Accumulation of microtubule-associated protein tau has been observed in the brain of aging and tauopathies. Tau was observed in microglia, but its role is not illustrated. By immunofluorescence staining and the fractal dimension value assay in the present study, we observed that microglia were activated in the brains of rats and mice during aging, simultaneously, the immunoreactivities of total tau and the phosphorylated tau were significantly enhanced in the activated microglia. Furtherly by transient transfection of tau40 (human 2N/4R tau) into the cultured rat microglia, we demonstrated that expression of tau40 increased the level of Iba1, indicating activation of microglia. Moreover, expression of tau40 significantly enhanced the membranous localization of the phosphorylated tau at Ser396 in microglia possibly by a mechanism involving protein phosphatase 2A, extracellular signal-regulated kinase and glycogen synthase kinase-3β. It was also found that expression of tau40 promoted microglial migration and phagocytosis, but not proliferation. And we observed increased secretion of several cytokines, including interleukin (IL)-1β, IL-6, IL-10, tumor necrosis factor-α and nitric oxide after the expression of tau40. These data suggest a novel role of human 2N/4R tau in microglial activation.
Citation: Wang L, Jiang Q, Chu J, Lin L, Li X-G, et al. (2013) Expression of Tau40 Induces Activation of Cultured Rat Microglial Cells. PLoS ONE 8(10): e76057. doi:10.1371/journal.pone.0076057
Editor: Michelle L. Block, Virginia Commonwealth University, United States of America
Received: March 7, 2013; Accepted: August 20, 2013; Published: October 11, 2013
Copyright: © 2013 Wang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported in part by grants from the Natural Science Foundation of China (grant number:30971204, 81271404)(http://www.nsfc.gov.cn/Portal0/default152.htm). No additional external funding received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
The ubiquitously distributed microglia are the representative of immune cells in the relatively immune-privileged central nervous system (CNS) and account for about 10% of the total glial population in the brain . They are recognized to be involved in innate immunity and surveillance of the parenchyma , . Microglia are sensitive to brain injury and disease, altering their morphology and phenotype to adopt a so-called activated state in response to brain insults. Activated microglia phagocytose the dying cells and debris and/or release some cytokines to maintain the homeostasis of microenvironment for supporting the injured neurons . Thus as an active sensor and monitor in the brain, activation of microglia is beneficial for the neuronal survival. However, lots of reports also implicated the neurotoxic roles of microglia in neurodegenerative diseases, such as Alzheimer's disease (AD) , , in which aging is the most important risk factor.
AD is characterized pathologically by extracellular senile plaques, intracellular neurofibrillary tangles (NFTs) and neuroinflammation , , . Microglia are found in a highly activated state in close anatomical proximity to senile plaques in AD brains, where they secrete numerous pro-inflammatory cytokines and chemokines . Thus it is thought that amyloid β (Aβ) deposits, the major component of senile plaques, constitute a chronic inflammatory stimulus triggering long-lasting activation of microglia that results in the production of neurotoxic substances, which contribute to the onset of neurodegeneration . However, the cognitive impairment of AD does not correlate with Aβ load but with presence of neurofibrillar pathology evident as tau-positive structures such as neuropil threads, neurofibrillary tangles and neuritic plaques , , , .
Tau, as the major microtubule-associated protein promoting the assembly and stabilization of microtubule, reduces its ability of stabilizing microtubule and leads to the disruption of the cytoskeletal arrangement when hyperphosphorylated , . Increased tau accumulation was reported in the brains of aging and several tauopathies including AD , , , , , . Tau pathology was found exacerbated by lipopolysaccharide (LPS)-induced inflammation , .
In the adult human brains, alternative splicing results in the appearance of six tau isoforms, which contain, respectively, 0, 1 or 2 amino-terminal inserts and 3 or 4 microtubule-binding repeats (0N/3R, 0N/4R, 1N/3R, 1N/4R, 2N/3R and 2N/4R). Tau was first found localized in neurons, specifically to axons , and later studies showed its presence in the somatodendritic compartment . Tau was subsequently found in glia , , and since then numerous studies have revealed abnormal accumulations of glial tau in various neurodegenerative diseases. In microglia tau assumes a particular conformation that is more readily identified by conformation-sensitive tau antibodies like Tau-66 and Tau-2 and is overlooked by tau antibodies such as Tau-5 , , . Futhermore, since not all microglia stain with Tau-66, it is likely that this conformation of tau is a marker for a particular pathological state. Tau-2 shows reactive microglia and Tau-66 shows from the seemingly non-reactive to fully reactive microglia and suggests that this change in tau conformation occurs early in the microglial activation process . These studies indicated the special role of tau in microglia, but no more research furtherly explains the effects of tau in microglia and its features, including the difference between microglial tau and that in neuron, astrocytes or oligodendrocytes, and the relations between the conformation and modification of microglial tau with the morphous and function of microglia.
In this study, we observed that microglia were activated in rats and mice during aging by immunofluorescence staining and the fractal dimension value assay. To explore the role of tau in microglia, we observed the immunoreactivities to total tau and the phosphorylated tau were significantly enhanced in activated microglia. As 4R tau is increased in the NFTs isolated from AD patients , , and the human tau40 (2N/4R, the longest isoform of human tau) transgenic mice recapitulate features of known neurodegenerative diseases, including AD and other tauopathies , we expressed tau40 in cultured rat microglial cells by transient transfection to study the role of tau in microglia during aging in vitro and demonstrated that expression of tau40 induced increasing of Iba1, indicating microglial activation. Furthermore, expression of tau40 significantly enhanced the membranous localization of the phosphorylated tau at Ser396 in microglia possibly by a mechanism involving protein phosphatase 2A (PP2A), extracellular signal-regulated kinase (ERK) and glycogen synthase kinase-3β (GSK-3β). It was also found expression of tau40 promoted microglial migration and phagocytosis, but not proliferation. And the secretion of several cytokines, including interleukin (IL)-1β, IL-6, IL-10, tumor necrosis factor-α (TNF-α) and nitric oxide (NO), were enhanced after tau40 expression. We have previously reported that expression of tau renders the cells more resistant to the chemically induced cell apoptosis , proving the new role of tau in cellular signal transduction rather than cytoskeleton. As both tau and activated microglia are increased in the brain during aging, the current data disclose the role of increased tau in microglial activation, which has not been reported previously.
Materials and Methods
All experimental procedures were approved by the Animal Care and Use Committee of Huazhong University of Science and Technology and were performed in compliance with National Institutes of Health guidelines for the ethical use of animals.
Antibodies, chemicals and plasmids
All primary antibodies employed in the study are listed in Table 1. The antibodies of tau used in this study (R134d, Tau46, AT8, pS396 and pT231) recognize tau from rat, human and mouse. Anti-rabbit, anti-mouse IgG conjugated to IRDye (800 CW) were purchased from LI-COR Biosciences (Lincoln, NE, USA). Oregon Green 488-conjugated goat anti-rabbit IgG and Rhodamine Red-X-conjugated goat anti-rabbit/mouse IgG were purchased from Molecular Probes (Eugene, OR, USA). Bicinchoninic acid (BCA) protein detection kit was purchased from Pierce Chemical Company (Rockford, IL, USA). ELISA kits were purchased from R&D Systems (Minneapolis, MN, USA). Lipofectamine 2000, carboxylate-modified 1 µm yellow-green fluorescent microspheres were purchased from Invitrogen (San Diego, CA, USA). Cell culture media were purchased from Gibico (Grand Island, NY, USA). NO assay kit, membrane and cytosol protein extraction kit were purchased from Beyotime Institute of Biotechnology (Nantong, Jiangsu, China). The enhanced green fluorescent protein (EGFP) labeled human tau40 (441 amino acids) was a kind gift from Dr. Fei Liu from Jiangsu Key Laboratory of Neuroregeneration (Nantong, Jiangsu, China). The red fluorescent protein (RFP) DsRed labeled human tau40 (441 amino acids) was constructed by ourselves. All of the other chemicals were the highest purity available commercially.
Table 1. Primary antibodies employed in this study and their properties.doi:10.1371/journal.pone.0076057.t001
Animals and treatments
SD rats (male, 4 months old and 14 months old) were obtained from the Experimental Animal Center of Tongji Medical College, Huazhong University of Science and Technology. C57BL/6 mice (male, 3 months old and 12 months old) were purchased from the Experimental Animal Center of Wuhan University. All the animals were kept under standard laboratory conditions (24±1°C, 12 h light/12 h dark cycle, light cycle begins at 06:00) with unrestricted access to food. For immunohistochemical studies, rats and mice were deeply anesthetized with intraperitoneal injection of chloral hydrate (360 mg/kg) and perfused through the aorta with 100 ml 0.9% NaCl followed by 400 ml phosphate buffer saline (PBS) containing 4% paraformaldehyde (pH 7.2, 4°C).
Cell culture and plasmids transfection
Rat microglia were purchased from Sciencell Research Laboratory, California, USA. They were grown at 37°C in 5% CO2 in DMEM (high glucose) supplemented with 10% FBS, penicillin at 100 units/ml and streptomycin at 100 µg/ml. Media were changed every 2 to 3 days after plating. The adherent cells were digested by D-Hank's containing 0.25% trypsogen, plated in cell plates at suitable densities, and incubated at 37°C in 5% CO2 until treatment. Vector and tau40 plasmids were transfected into microglia using Lipofectamine 2000 according to the protocol of the manufacturer (Invitrogen). At 24 h after transfection, cells were collected and used for further studies. By counting of the plated cells, the transfection efficiencies of the plasmids (vector and tau40) in this study were about 40%.
Brains of rats or mice were removed and postfixed in perfusate overnight and then cut into sections (25 µm) by vibratome (Leica, VT1000S, Germany). The sections were collected consecutively in phosphate buffer (PB) for immunofluorescence. They were incubated overnight at 4°C with primary antibodies.
For cell studies, cells were cultured on coverslips and fixed with 4% paraformaldehyde for 20 min, permeabilized with 0.5% Triton X-100, and then incubated with primary antibodies overnight at 4°C.
After washing with PBS, brain sections or cells were subsequently incubated with Rhodamine Red-X- or Oregon Green 488-conjugated secondary antibodies (1:1000) for 1 h at 37°C. The images were observed by laser confocal microscope (LSM710, Zeiss, Germany) and the fluorescence intensity was analyzed by the software affiliated. The fractal dimension value of microglia was analyzed by Image Pro Plus 6.0 (Media Cybernetics, Silver Spring, MD, USA).
We harvested the cells and lysed them with sample buffer containing 50 mM Tris-HCl (pH 7.6), 2% sodium dodecyl sulfate (SDS), 10% glycerol, 3 mM PMSF and 0.2% bromophenol blue. After they had been boiled for 10 min, the cell lysates were ultrasonic processed for 15 s. The protein concentration of the cell lysates was estimated by BCA kit. The proteins were separated by 10% SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose (NC) membrane, blocked in TBS (50 mM Tris-HCl, pH 7.6, 150 mM NaCl) containing 5% skimmed milk for 40 min. After they had been washed with distilled water, the blots were incubated with primary antibodies at 4°C overnight. After they had been washed 3 times with TBS containing Tween-20 (0.2%), the blots were probed by using IRDye 800CW-conjugated secondary antibodies (1:10000) for 1 h. The blots were visualized using infrared fluorescence imaging and the intensity of them was quantified by Odyssey infrared imaging system (Li-Cor Bioscience, Lincoln, NE, USA). The levels of the proteins were expressed as relative levels of the sum optical density against controls.
Membranous and cytosolic protein extraction
Rat microglia were resuspended in solution A contained 1 mM PMSF and mechanically dissociated by trituration. They were centrifuged at 700 g for 10 min at 4°C to remove unbroken cells and nucleis. Supernatant were centrifuged at 14000 g for 30 min at 4°C to precipitate membrane fragments. Supernatant were collected as cytosolic protein, sediment were centrifuged at 14000 g for 10 s at 4°C and added 1/5 (v/v) of solution B with frequent vortexing for 5 s and incubated on ice for 10 min, then vortexing and ice-incubating were repeated. The solution was centrifuged at 14000 g for 5 min at 4°C and supernatant were collected as membrane protein.
In vitro scratch assay
Rat microglia were cultured as confluent monolayers in culture dishes and transfected with vector/tau40-encoding EGFP fusion protein for 24 h, and then scratched with a 100 µl pipette tip. The scratched monolayers were washed twice to remove non-adherent cells and media were changed with DMEM , . Then the cells were observed by laser confocal microscope (LSM510, Zeiss, Germany) and analyzed of the cell migration at 0 h, 6 h, 12 h, and 24 h separately. Phase contrast and fluorescence images were taken at the different time points until the wound closed. The wounded area was defined in each image by positioning lines in correspondence to the original scratch and the following data were analyzed by Image Pro Plus 6.0.
Rat microglia were collected and plated in cell plates and then transfected with vector/tau40-encoding RFP fusion protein. At 24 h after transfection, media were changed with DMEM. The cells were then treated at 37°C for 30 min with 1 µm yellow-green fluorescent microspheres. After incubation, microspheres were washed with PBS and then fixed with 4% paraformaldehyde for 20 min. The fluorescent microspheres were excited very efficiently using the 488 nm spectral line of the argon-ion laser and had exceptionally intense fluorescence. Analysis of phagocytized particles had been carried out by fluorescence microscope (Zeiss, Germany) and quantitative flow cytometer (BD Biosciences, USA).
ELISA and NO assay
For ELISA assay, supernatant of rat microglial cells were collected as sample. 50 µl of diluent 1× and 50 µl of standard or sample were added to each well. After being incubated at 37°C for 30 min, each well were aspirated and washed for 30 s ×5 with wash solution (400 µl). After the last wash, any remaining wash buffer was removed by aspirating or decanting. Then 100 µl of rat IL-1β/IL-6/TNF-α/IL-10 conjugate was added to each well. After being incubated at 37°C for 30 min, aspiration and washing were repeated. 100 µl of substrate solution was added to each well. After being incubated at 37°C for 10 min (protect from light), 100 µl of stop solution was added to each well. The color in the wells should change from blue to yellow. We used a microplate reader (Biotek, Winooski, VT, USA) set to 450 nm to determine the optical density of each well within 30 min. A standard curve was prepared from standard dilutions of cytokines in duplicate. The cytokine concentration in each sample was determined from the standard curve.
The level of NO was measured according to the protocol of the manufacturer (Beyotime). We used a microplate reader set to 540 nm to determine the optical density of each well within 30 min. A standard curve was prepared from standard dilutions of NO in duplicate. The concentration of NO in each sample was determined from the standard curve.
At 24 h after transfection, the medium of rat microglial cells was collected and centrifuged at 300 g for 5 min. 5 µl of supernatant was applied to the marked circle on NC membrane and dried before being blocked. Then the NC membranes were incubated with antibodies as introduced in Western blotting.
Data were analyzed by using SPSS 12.0 statistical software (SPSS, Chicago, IL, USA). All data were expressed as means ± S.D.. Statistical significance was determined by Student's two-tailed t-test with 95% confidence.
Microglia are activated during aging and tau accumulates in activated microglia
Microglial activation has been observed in the brains of aging ,  and AD patients . By using the antibody of Iba1, a specific marker of microglia , we stained the brain slices of rats and mice at different ages (Figure 1A, D). Normally, ramified microglia with small soma and arborescent processes are resting microglia. Ameboid microglia with larger soma and less processes are regarded as activated microglia , , . By fractal dimension value analysis for evaluation of microglial activation , , we found more microglia with lower fractal dimension value in elder rats and mice (Figure 1B, C, E, F), indicating microglial activation in the brains of the elder animals.
Figure 1. Activation of microglia in the brains of rats and mice with aging.
Microglia in the cortex of 4- and 14-month-old SD rats (A), 3- and 12-month-old C57BL/6 mice (D) were immunostained by Iba1, a marker of microglia (Scale bar = 100 µm). The fractal dimension value analysis was used to evaluate the activation of microglia in the brains of different group of animals. Lower fractal dimension value indicates higher activity of microglia. We divided the fractal dimension value of the microglia into four grades (>1.3, 1.2–1.3, 1.1–1.2, <1.1), and the percentages of microglia with different grades were shown in B and E, the differences of the same grade between the different age of animals were shown in C and F (n>43 cells/group). Data were presented as means ± S.D.. * p<0.05, ** p<0.01 versus 4-month-old SD rats/3-month-old C57BL/6 mice.doi:10.1371/journal.pone.0076057.g001
Previous studies demonstrated that level of tau protein was increased in the aged brain and the increase was more significant in the brain of AD , , , . To measure the level of tau in microglia, we double-stained the brain slices with the antibody recognizing total tau (Tau46) or phosphorylated tau (AT8) and the antibody recognizing microglia (Iba1). Positive immunoreactions to Tau46 and AT8 were observed in different types of microglia (Figure 2A, C, E, G). From Figure 1B, E and Figure 2B, D, F, H, we found the level of total tau (recognized by Tau46) in microglia of the 14 months old rats is 1.18 times of that in 4 months old rats, and the phosphorylated tau (recognized by AT8) is 1.15 times. The level of total tau of microglia in 12 months old C57BL/6 mice is 1.19 times of that in 3 months old mice, and the phosphorylated tau is 1.21 times. However, the levels of total tau and phosphorylated tau in microglia with lowest fractal dimension value were highest (Figure 2B, D, F, H).
Figure 2. Both total tau and phosphorylated tau increase in activated microglia.
Microglia in the brain slices were co-immunostained with Iba1 (green) and Tau46 (an antibody recognizing total tau) or AT8 (an antibody recognizing phosphorylated tau at Ser202/Thr205) (red). In contrast with the ramified microglia (arrow heads), ameboid microglia (arrows) showed increased total tau (A, C) and the phosphorylated tau (E, G) (Scale bar = 20 µm). The relative levels of integrated optical density (IOD) of Tau46/AT8 in microglia with different grades of fractal dimension value were shown in B, D, F, H. Data were presented as means ± S.D.. ** p<0.01 versus microglia with fractal dimension value <1.1.doi:10.1371/journal.pone.0076057.g002
Expression of tau40 activates microglia with membranous accumulation of phosphorylated tau
To verify the effects of tau on microglial activation, we measured the level of Iba1 after transient expression of tau40 or the vector (as control) in the cultured rat microglia. The level of Iba1 was significantly increased at 24 h after transfection (Figure 3), indicating the activation of microglia. By immunofluorescence staining, we noticed that the endogenous tau phosphorylated at Ser396 was uniformly distributed in the cytoplasma of the vector-transfected and un-transfected microglia, while expression of exogenous tau resulted in membranous accumulation of phosphorylated tau at Ser396 (Figure 4A). To further verify the distribution of tau in microglia, we isolated membranous fraction from cytosolic fraction after transfection of tau40 or vector and measured the level of tau in different fractions. DM1A and pan-Cadherin were used as makers of cytoplasma and membrane, respectively. Expression of tau40 significantly increased the phosphorylation of tau at Ser396 in membrane fraction (Figure 4B, C). To investigate the possible mechanism, we measured the activity-related phosphorylation levels of PP2A, ERK and GSK-3β, which are highly involved enzymes in tau phosphorylation (Figure 4D). The levels of phosphorylated PP2A catalytic subunit (PP2Ac) at Thr307 and phosphorylated ERK at Thr202/Tyr204 were significantly increased, while the phosphorylated GSK-3β at Ser9 was decreased, indicating inhibition of PP2A and activation of ERK and GSK-3β (Figure 4E). These data together suggested that tau40 activated microglia and caused membranous accumulation of phosphorylated tau possibly by a mechanism involving PP2A, ERK and GSK-3β.
Figure 3. Expression of tau40 induces increased Iba1.
In cultured rat microglia, the plasmid of human tau40 (441 amino acids) or vector was transfected for 24 h. Then the levels of total tau probed by R134d and Iba1, a marker of microglial activation, were measured by Western blotting (A) and quantitative analysis (B) respectively. The alteration of Iba1 was normalized against DM1A. The experiments were repeated at least three times and data were presented as means ± S.D.. * p<0.05 versus vector-transfected cells.doi:10.1371/journal.pone.0076057.g003
Figure 4. Expression of tau40 induces membranous accumulation of phosphorylated tau, simultaneously with inhibition of PP2A and activation of ERK and GSK-3β.
In cultured rat microglial cells, the plasmid of human tau40-EGFP (T) or vector-EGFP (V) was transfected. 24 h later, triple immunofluorescence imaging was performed. The nucleus was stained with Hoechst (blue) and the phosphorylated tau was probed by pS396 (an antibody recognizing phosphorylated tau at Ser396) (red). Then cells were observed by confocal microscope (A) (Scale bar = 20 µm). The membranous (m) and cytoplasma (p) fractions were isolated as described in the method and the level of pS396 in the two fractions was analyzed by Western blotting (B) and quantitative analysis (C). The levels of PP2Ac, p-PP2Ac (Y307), ERK, p-ERK, GSK-3β and p-GSK-3β (S9) were probed and measured by Western blotting (D) and quantitative analysis (E). The data were representative of three independent experiments and were presented as means ± S.D.. * p<0.05 versus vector-transfected cells.doi:10.1371/journal.pone.0076057.g004
Expression of tau40 promotes migration, phagocytosis and secretion of microglia
Actived microglial cell presents high ability of migration, phagocytosis and secretion . To explore the role of tau40 in microglial migration, we used the in vitro scratch assay as reported and calculated the average migration rate in different time intervals and the total migration distance within 24 h . We observed that expression of tau40 accelerated microglial migration toward the center of the wound and the average speeds were ~1.6-fold in 0–6 h, ~2.0-fold in 6–12 h and 12–24 h of the control (vector transfected) microglia. In 24 h, the control microglia moved about 277 µm, while the microglia with expression of tau40 moved about 543 µm (Figure 5). By cell counting, no difference in proliferation was seen between two groups (not shown). These data indicated that tau40 accelerated microglial migration in culture.
Figure 5. Expression of tau40 promotes migration of microglia.
In cultured rat microglia, the plasmid of human tau40-EGFP or vector-EGFP was transfected for 24 h. Then in vitro scratch assay was performed and the images of migration were captured at 0 h, 6 h, 12 h and 24 h after scratching with confocal microscope (A) (Scale bar = 100 µm). The migration rate of microglia was quantified by the distance that the EGFP positive cells moved from the edge of the scratch towards the center per hour. The average migration rates of the EGFP positive microglia in 0–6 h, 6–12 h and 12–24 h were calculated from three independent experiments (B). Data were presented as means ± S.D.. * p<0.05, ** p<0.01 versus vector-transfected cells.doi:10.1371/journal.pone.0076057.g005
Microglial cells are recognized phagocytes in CNS and this function is important for the normal brain during the development, pathology and regeneration of brain , . To explore the effect of tau40 on phagocytosis of microglia, we constructed the plasmid of vector/tau40-encoding RFP fusion protein and transfected the plasmids into the cultured rat microglial cells for 24 h, and then 1 µM yellow-green fluorescent microspheres were added and incubated at 37°C for 30 min. It was observed that microglia expressing tau40 phagocytized more microspheres than vector-transfected and un-transfected cells by fluorescence microscope, and there was no difference between vector-transfected and un-transfected cells (Figure 6A, B). We furtherly used quantitative flow cytometry to analyze the percentage and the index of phagocytosis (Figure 6C, D). The results showed that single tau40-expressing cell phagocytized more fluorescent beads than the vector-transfected cell. However, there was no significant difference in the percentage of the cells phagocytized beads between two groups (Figure 6E, F). These data suggested that expression of tau40 enhanced the phagocytic capacity of microglia.
Figure 6. Expression of tau40 enhances phagocytosis of microglia.
In cultured rat microglia, the plasmid of human tau40-RFP or vector-RFP was transfected. 24 h later, yellow-green fluorescent beads with the diameter of 1 µm were added into the medium. After being incubated at 37°C for 30 min, the phagocytosis of microglia was observed by fluorescence microscopy (A, B) (Scale bar = 20 µm) and quantitatively analyzed by flow cytometry (C, D) respectively. The percentage of transfected microglia containing green fluorescence (E) and the average green fluorescent intensity of single transfected microglia (F) were calculated from three independent experiments. Data were presented as means ± S.D.. ** p<0.01 versus vector-transfected cells.doi:10.1371/journal.pone.0076057.g006
Actived microglia could release cytokines, which have been classified based on their actions in peripheral tissues as either anti-inflammatory cytokines, such as IL-4, IL-10, or pro-inflammatory cytokines, such as IL-1β, IL-6, TNF-α and NO . We measured the levels of inflammatory cytokines in the medium at 24 h after transfection of tau40 or the vector. Obvious increased levels of IL-1β, IL-6, TNF-α, IL-10 and NO were detected in the medium after tau40 transfection (Figure 7A–E). Recent studies suggested that tau could be released from viable cells , , . To verify if tau could be released from microglia, we measured the levels of total tau (recognized by R134d) and phosphorylated tau (recognized by pS396 and pT231) in the medium by dot blot (Figure 7F). It was shown that both vector and tau40 transfected cells released tau, and the later released more tau. By calculating the ratio of phosphorylated tau, the levels of released tau phosphorylated at Ser396 and Thr231 epitopes were lower in tau40 expressing cells (Figure 7G). Taken together with previous data (Figure 4A, B, C), it is possible that tau40 transfected cells released unphosphorylated tau and kept more phosphorylated tau in themselves.
Figure 7. Expression of tau40 increases the levels of inflammatory cytokines and tau in the medium.
In cultured rat microglial cells, the plasmid of human tau40-EGFP or vector-EGFP was transfected. 24 h after transfection, levels of IL-1β (A), IL-6 (B), TNF-α (C) and IL-10 (D) in the supernatant of medium were assessed by ELISA. And the concentration of NO (E) was represented by nitrite which was determined by Griess reaction. The release of tau (R134d) and its phosphorylation at Ser396 (pS396) and Thr231 (pT231) in the medium were assessed by dot blot (F) and quantitative analysis (G). The experiments were repeated at least three times, and data were presented as means ± S.D.. * p<0.05, ** p<0.01 versus vector-transfected cells.doi:10.1371/journal.pone.0076057.g007
In present study, we found that microglia were activated in the brains of rats and mice with aging, simultaneously the increase of tau was shown in the activated microglia. Further studies in the cultured rat microglia demonstrated that expression of tau40 induced activation of microglia with accelerated migration, enhanced phagocytosis, increased secretion of inflammatory cytokines and unphosphorylated tau, and the activation of ERK and GSK-3β. Our data suggest that tau40 may serve as an upstream factor to trigger microglial activation during aging and AD.
Tau is often detected in the axon and dendrite of neuron , . It has recently been identified on the plasma membrane , , . Here, our data showed that tau40 in microglia induced increased phosphorylation of tau at Ser396, which is predominantly located on the plasma membrane.
Some kinases in microglia could phosphorylate tau proteins, such as ERK1/2 and GSK-3β . ERK is a mitogen-activated protein kinase (MAPK) and and phosphorylation of ERK is an early event in the activation of microglia , . GSK-3 is an important serine/threonine protein kinase phosphorylating tau at the majority of AD-related sites . The role of GSK-3β in inflammation was reported firstly in 2005 . Activation of GSK-3β modulates the nuclear translocation of nuclear factor-κB (NF-κB) and cAMP-response element binding protein (CREB) by enabing CREB binding protein (CBP) to bind both transcriptional factors, which facilitates nuclear translocation and increases the production and transcription of pro-inflammatory cytokines . PP2A is the main protein phosphatase involved in tau phosphorylation, and the activity of PP2A is decreasesd in AD , , . In present study, the activation of ERK and GSK-3β and inhibition of PP2A were detected in tau40 transfected microglial cells, which might contribute to the increased phosphorylation of tau at Ser 396. The mechanism involved in activation of ERK and GSK-3β and inhibition of PP2A in microglia requests further studies.
After activation, microglial cell will migrate to the site of injury or inflammation . Cell motility is a dynamic process driven by structurally and functionally coordinated reorganization of the actin cytoskeleton , . Many of the pro-migratory factors are members of the chemokine family. Therefore, we tested whether tau40 could regulate the migration of the cultured microglia and found that tau40 remarkably accelerated the migration. It is reported that tau may act to facilitate neuronal migration synergistically . Phagocytosis is another important function of microglia. In the AD brain, microglia increased and clustered in and around Aβ deposits , . In a P301S tauopathy mouse model, exhibiting certain aspects of neurofibrillary tangle formation of AD, early microglial activation was associated with loss of synapses . There were also evidences indicating that accumulation of microglia in AD might be protective and promote Aβ clearance , , . In our current study, we found tau40 transfected microglia showed stronger phagocytosis. It is currently not understand how tau40 enhances phagocytosis of microglial cells.
Gene array studies have shown that various cytokines are elevated in aged rodent brains , , and the protein levels of both anti-inflammatory cytokines (e. g. IL-10) and pro-inflammatory cytokines (e.g. IL-1β, TNF-α and IL-6) are elevated during aging . In the present study tau40 increased the levels of both anti-inflammatory cytokines (IL-10) and pro-inflammatory cytokines (IL-1β, TNF-α, IL-6 and NO). IL-1β has long been recognized as a key mediator of immune and inflammatory responses during infection. In the CNS, IL-1β is mainly expressed and released by microglia, although astrocytes and neurons may also contribute to production of IL-1β, particularly in the late phase after excitotoxicity . In the early phase of CNS injury, microglia release IL-6 , a multifunctional cytokine with diverse actions including the regulation of inflammation, immune responses and cell differentiation. TNF-α could be produced by neurons, astrocytes, and microglia in the CNS , and low level of TNF-α has neuroprotective consequences . NO is generated by inducible nitric oxide synthase (iNOS) in microglia, and a wide variety of neurologic injuries or diseases are associated with the induction of iNOS and the generation of NO by microglia , . Compared with LPS treatment, a classical activator of microglia, the magnitudes of changes in inflammatory factors induced by tau40 in this study were relatively modest. We have reported that overexpression of tau can protect the cells from an acute apoptosis . It will be interesting in further studies to investigate whether and how the tau-induced cytokines release from microglia affect the viability of neurons or other types of glial cells or microglia itself.
In AD the mechanism involved in the spreading of tau pathology is unknown. It is speculated that tau, the primary component of NFTs, is released following neuronal death, allowing it to be taken up by neighbouring cells including microglia . Tau released from healthy neurons could be a physiological process that might be disrupted in diseased brain. Total tau and hyperphosphorylated tau in cerebrospinal fluid (CSF) have been shown to correlate with neurofibrillary pathology in AD , . Thus it is possible that microglia can phagocytize tau released by neuron and/or glia, which leading to the activation of microglia during aging.
It was reported that tau assumes a particular conformation that is more readily identified by conformation-sentitive tau antibodies like Tau-66 and Tau-2 and is overlooked by tau antibodies such as Tau-5 in microglia , , . Tau-2 shows reactive microglia and Tau-66 shows from the seemingly non-reactive to fully reactive microglia, which suggests that this change in tau conformation occurs early in the microglial activation process . As Tau-2 positive microglia-like cells (TPMCs) do not react with conventional anti-tau antibodies and is devoid of fibrils composed of hyperphosphorylated tau, TPMCs are also thought to represent a conformational state that can be reversibly diminished upon exposure to a detergent and may instead represent a secondary event shared with ischemic/inflammatory foci. Thus, it is highly debatable whether tau proteins are the principal constituents of these TMPCs. Here, we found more total tau and phosphorylated tau in activated microglia with lower fractal dimension value. As we did not have human brain sample or human microglia cell line, we expressed tau40 in cultured rat microglial cells by transient transfection and observed increasing of Iba1 level and increased microglial migration, phagocytosis and secretion, indicating the activation of microglia after tau40 transfection. If human microglia cell cultures were used, the results may be more persuasive. Totally, all these data of this research indicate tau is important for microglial activation in aging and AD, which have not been substantially replicated in the previous literature. But the role of phosphorylated tau in microglial activation needs further investigation.
We thank Dr. Iqbal (New York State Institute for Basic Research in Developmental Disabilities, USA) for the antibody R134d.
Conceived and designed the experiments: JZW QT. Performed the experiments: LW QJ JC LL QW XGL GSC QT. Analyzed the data: LW QT. Wrote the paper: LW JZW QT.
- 1. Vaughan DW, Peters A (1974) Neuroglial cells in the cerebral cortex of rats from young adulthood to old age: an electron microscope study. J Neurocytol 3: 405–429. doi: 10.1007/bf01098730
- 2. Becher B, Prat A, Antel JP (2000) Brain-immune connection: immuno-regulatory properties of CNS-resident cells. Glia 29: 293–304. doi: 10.1002/(sici)1098-1136(20000215)29:4<293::aid-glia1>3.0.co;2-a
- 3. Aloisi F (2001) Immune function of microglia. Glia 36: 165–179.
- 4. Koizumi S, Shigemoto-Mogami Y, Nasu-Tada K, Shinozaki Y, Ohsawa K, et al. (2007) UDP acting at P2Y6 receptors is a mediator of microglial phagocytosis. Nature 446: 1091–1095.
- 5. McGeer PL, Rogers J, McGeer EG (2006) Inflammation, anti-inflammatory agents and Alzheimer disease: the last 12 years. J Alzheimers Dis 9: 271–276.
- 6. Kim YS, Joh TH (2006) Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson's disease. Exp Mol Med 38: 333–347.
- 7. Terry RD, Katzman R (1983) Senile dementia of the Alzheimer type. Ann Neurol 14: 497–506.
- 8. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, et al. (1986) Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A 83: 4913–4917. doi: 10.1073/pnas.83.13.4913
- 9. Wyss-Coray T (2006) Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med 12: 1005–1015. doi: 10.1016/0197-4580(92)90027-u
- 10. Meda L, Cassatella MA, Szendrei GI, Otvos LJ, Baron P, et al. (1995) Activation of microglial cells by beta-amyloid protein and interferon-gamma. Nature 374: 647–650. doi: 10.1038/374647a0
- 11. Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82: 239–259. doi: 10.1007/bf00308809
- 12. Dickson DW, Crystal HA, Mattiace LA, Masur DM, Blau AD, et al. (1992) Identification of normal and pathological aging in prospectively studied nondemented elderly humans. Neurobiol Aging 13: 179–189. doi: 10.1016/0197-4580(92)90027-u
- 13. Riley KP, Snowdon DA, Markesbery WR (2002) Alzheimer's neurofibrillary pathology and the spectrum of cognitive function: findings from the Nun Study. Ann Neurol 51: 567–577.
- 14. Grober E, Dickson D, Sliwinski MJ, Buschke H, Katz M, et al. (1999) Memory and mental status correlates of modified Braak staging. Neurobiol Aging 20: 573–579.
- 15. Bramblett GT, Goedert M, Jakes R, Merrick SE, Trojanowski JQ, et al. (1993) Abnormal tau phosphorylation at Ser396 in Alzheimer's disease recapitulates development and contributes to reduced microtubule binding. Neuron 10: 1089–1099.
- 16. Goedert M, Spillantini MG, Jakes R, Crowther RA, Vanmechelen E, et al. (1995) Molecular dissection of the paired helical filament. Neurobiol Aging 16: 325–334.
- 17. Maeda S, Sahara N, Saito Y, Murayama S, Ikai A, et al. (2006) Increased levels of granular tau oligomers: an early sign of brain aging and Alzheimer's disease. Neurosci Res 54: 197–201.
- 18. Berger Z, Roder H, Hanna A, Carlson A, Rangachari V, et al. (2007) Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. J Neurosci 27: 3650–3662. doi: 10.1523/jneurosci.0587-07.2007
- 19. Shin RW, Ogomori K, Kitamoto T, Tateishi J (1989) Increased tau accumulation in senile plaques as a hallmark in Alzheimer's disease. Am J Pathol 134: 1365–1371. doi: 10.1073/pnas.83.11.4044
- 20. Mitchell TW, Mufson EJ, Schneider JA, Cochran EJ, Nissanov J, et al. (2002) Parahippocampal tau pathology in healthy aging, mild cognitive impairment, and early Alzheimer's disease. Ann Neurol 51: 182–189. doi: 10.1002/ana.10086
- 21. Kosik KS, Joachim CL, Selkoe DJ (1986) Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc Natl Acad Sci U S A 83: 4044–4048. doi: 10.1073/pnas.83.11.4044
- 22. Sjogren M, Davidsson P, Tullberg M, Minthon L, Wallin A, et al. (2001) Both total and phosphorylated tau are increased in Alzheimer's disease. J Neurol Neurosurg Psychiatry 70: 624–630. doi: 10.1136/jnnp.70.5.624
- 23. Kitazawa M, Oddo S, Yamasaki TR, Green KN, LaFerla FM (2005) Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J Neurosci 25: 8843–8853.
- 24. Lee DC, Rizer J, Selenica ML, Reid P, Kraft C, et al. (2010) LPS- induced inflammation exacerbates phospho-tau pathology in rTg4510 mice. J Neuroinflammation 7: 56.
- 25. Binder LI, Frankfurter A, Rebhun LI (1985) The distribution of tau in the mammalian central nervous system. J Cell Biol 101: 1371–1378.
- 26. Papasozomenos SC, Binder LI (1987) Phosphorylation determines two distinct species of Tau in the central nervous system. Cell Motil Cytoskeleton 8: 210–226.
- 27. LoPresti P, Szuchet S, Papasozomenos SC, Zinkowski RP, Binder LI (1995) Functional implications for the microtubule-associated protein tau: localization in oligodendrocytes. Proc Natl Acad Sci U S A 92: 10369–10373.
- 28. Odawara T, Iseki E, Kosaka K, Akiyama H, Ikeda K, et al. (1995) Investigation of tau-2 positive microglia-like cells in the subcortical nuclei of human neurodegenerative disorders. Neurosci Lett 192: 145–148. doi: 10.1016/0304-3940(95)11595-n
- 29. Ghoshal N, Garcia-Sierra F, Fu Y, Beckett LA, Mufson EJ, et al. (2001) Tau-66: evidence for a novel tau conformation in Alzheimer's disease. J Neurochem 77: 1372–1385. doi: 10.1046/j.1471-4159.2001.00346.x
- 30. Uchihara T, Tsuchiya K, Nakamura A, Ikeda K (2000) Appearance of tau-2 immunoreactivity in glial cells in human brain with cerebral infarction. Neurosci Lett 286: 99–102. doi: 10.1016/s0304-3940(00)01103-4
- 31. Iseki E, Yamamoto R, Murayama N, Minegishi M, Togo T, et al. (2006) Immunohistochemical investigation of neurofibrillary tangles and their tau isoforms in brains of limbic neurofibrillary tangle dementia. Neurosci Lett 405: 29–33. doi: 10.1016/j.neulet.2006.06.036
- 32. Yoshida M (2006) Cellular tau pathology and immunohistochemical study of tau isoforms in sporadic tauopathies. Neuropathology 26: 457–470. doi: 10.1111/j.1440-1789.2006.00743.x
- 33. Spittaels K, Van den Haute C, Van Dorpe J, Bruynseels K, Vandezande K, et al. (1999) Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein. Am J Pathol 155: 2153–2165.
- 34. Li HL, Wang HH, Liu SJ, Deng YQ, Zhang YJ, et al. (2007) Phosphorylation of tau antagonizes apoptosis by stabilizing beta-catenin, a mechanism involved in Alzheimer's neurodegeneration. Proc Natl Acad Sci U S A 104: 3591–3596.
- 35. Liang CC, Park AY, Guan JL (2007) In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc 2: 329–333.
- 36. Abbi S, Ueda H, Zheng C, Cooper LA, Zhao J, et al. (2002) Regulation of focal adhesion kinase by a novel protein inhibitor FIP200. Mol Biol Cell 13: 3178–3191.
- 37. Sloane JA, Hollander W, Moss MB, Rosene DL, Abraham CR (1999) Increased microglial activation and protein nitration in white matter of the aging monkey. Neurobiol Aging 20: 395–405.
- 38. Lucin KM, Wyss-Coray T (2009) Immune activation in brain aging and neurodegeneration: too much or too little? Neuron 64: 110–122. doi: 10.1016/j.neuron.2009.08.039
- 39. El KJ, Toft M, Hickman SE, Means TK, Terada K, et al. (2007) Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med 13: 432–438. doi: 10.1038/nm1555
- 40. Babcock AA, Kuziel WA, Rivest S, Owens T (2003) Chemokine expression by glial cells directs leukocytes to sites of axonal injury in the CNS. J Neurosci 23: 7922–7930. doi: 10.1126/science.1110647
- 41. Nimmerjahn A, Kirchhoff F, Helmchen F (2005) Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 308: 1314–1318. doi: 10.1126/science.1110647
- 42. Davalos D, Grutzendler J, Yang G, Kim JV, Zuo Y, et al. (2005) ATP mediates rapid microglial response to local brain injury in vivo. Nat Neurosci 8: 752–758. doi: 10.1038/nn1472
- 43. Streit WJ, Walter SA, Pennell NA (1999) Reactive microgliosis. Prog Neurobiol 57: 563–581. doi: 10.1111/j.1753-4887.1996.tb03899.x
- 44. Soltys Z, Ziaja M, Pawlinski R, Setkowicz Z, Janeczko K (2001) Morphology of reactive microglia in the injured cerebral cortex. Fractal analysis and complementary quantitative methods. J Neurosci Res 63: 90–97. doi: 10.1111/j.1753-4887.1996.tb03899.x
- 45. Bhaskar K, Konerth M, Kokiko-Cochran ON, Cardona A, Ransohoff RM, et al. (2010) Regulation of tau pathology by the microglial fractalkine receptor. Neuron 68: 19–31. doi: 10.1111/j.1753-4887.1996.tb03899.x
- 46. Tesseur I, Van Dorpe J, Spittaels K, Van den Haute C, Moechars D, et al. (2000) Expression of human apolipoprotein E4 in neurons causes hyperphosphorylation of protein tau in the brains of transgenic mice. Am J Pathol 156: 951–964. doi: 10.1111/j.1753-4887.1996.tb03899.x
- 47. Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, et al. (2001) Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293: 1487–1491. doi: 10.1111/j.1753-4887.1996.tb03899.x
- 48. Sjogren M, Vanderstichele H, Agren H, Zachrisson O, Edsbagge M, et al. (2001) Tau and Abeta42 in cerebrospinal fluid from healthy adults 21–93 years of age: establishment of reference values. Clin Chem 47: 1776–1781.
- 49. Hu YY, He SS, Wang X, Duan QH, Grundke-Iqbal I, et al. (2002) Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients: an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay. Am J Pathol 160: 1269–1278. doi: 10.1016/s0002-9440(10)62554-0
- 50. Todaro GJ, Lazar GK, Green H (1965) The initiation of cell division in a contact-inhibited mammalian cell line. J Cell Physiol 66: 325–333. doi: 10.1002/jcp.1030660310
- 51. Napoli I, Neumann H (2009) Microglial clearance function in health and disease. Neuroscience 158: 1030–1038. doi: 10.1016/j.neuroscience.2008.06.046
- 52. Neumann H, Kotter MR, Franklin RJ (2009) Debris clearance by microglia: an essential link between degeneration and regeneration. Brain 132: 288–295. doi: 10.1093/brain/awn109
- 53. Smith JA, Das A, Ray SK, Banik NL (2012) Role of pro-inflammatory cytokines released from microglia in neurodegenerative diseases. Brain Res Bull 87: 10–20. doi: 10.1016/j.brainresbull.2011.10.004
- 54. Simon D, Garcia-Garcia E, Royo F, Falcon-Perez JM, Avila J (2012) Proteostasis of tau. Tau overexpression results in its secretion via membrane vesicles. FEBS Lett 586: 47–54. doi: 10.1016/j.febslet.2011.11.022
- 55. Lee S, Kim W, Li Z, Hall GF (2012) Accumulation of vesicle-associated human tau in distal dendrites drives degeneration and tau secretion in an in situ cellular tauopathy model. Int J Alzheimers Dis 2012: 172837. doi: 10.1155/2012/172837
- 56. Saman S, Kim W, Raya M, Visnick Y, Miro S, et al. (2012) Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease. J Biol Chem 287: 3842–3849. doi: 10.1074/jbc.m111.277061
- 57. Hirokawa N, Funakoshi T, Sato-Harada R, Kanai Y (1996) Selective stabilization of tau in axons and microtubule-associated protein 2C in cell bodies and dendrites contributes to polarized localization of cytoskeletal proteins in mature neurons. J Cell Biol 132: 667–679. doi: 10.1083/jcb.132.4.667
- 58. Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, et al. (2010) Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 142: 387–397. doi: 10.1016/j.cell.2010.06.036
- 59. Arrasate M, Perez M, Avila J (2000) Tau dephosphorylation at tau-1 site correlates with its association to cell membrane. Neurochem Res 25: 43–50. doi: 10.1016/j.neuint.2006.10.002
- 60. Brandt R, Leger J, Lee G (1995) Interaction of tau with the neural plasma membrane mediated by tau's amino-terminal projection domain. J Cell Biol 131: 1327–1340. doi: 10.1083/jcb.131.5.1327
- 61. Maas T, Eidenmuller J, Brandt R (2000) Interaction of tau with the neural membrane cortex is regulated by phosphorylation at sites that are modified in paired helical filaments. J Biol Chem 275: 15733–15740. doi: 10.1074/jbc.m000389200
- 62. Crespo-Biel N, Canudas AM, Camins A, Pallas M (2007) Kainate induces AKT, ERK and cdk5/GSK3beta pathway deregulation, phosphorylates tau protein in mouse hippocampus. Neurochem Int 50: 435–442. doi: 10.1016/j.neuint.2006.10.002
- 63. Song X, Tanaka S, Cox D, Lee SC (2004) Fcgamma receptor signaling in primary human microglia: differential roles of PI-3K and Ras/ERK MAPK pathways in phagocytosis and chemokine induction. J Leukoc Biol 75: 1147–1155. doi: 10.1189/jlb.0403128
- 64. Farber K, Kettenmann H (2005) Physiology of microglial cells. Brain Res Brain Res Rev 48: 133–143. doi: 10.1016/j.brainresrev.2004.12.003
- 65. Liu SJ, Zhang AH, Li HL, Wang Q, Deng HM, et al. (2003) Overactivation of glycogen synthase kinase-3 by inhibition of phosphoinositol-3 kinase and protein kinase C leads to hyperphosphorylation of tau and impairment of spatial memory. J Neurochem 87: 1333–1344. doi: 10.1046/j.1471-4159.2003.02070.x
- 66. Martin M, Rehani K, Jope RS, Michalek SM (2005) Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat Immunol 6: 777–784. doi: 10.1038/ni1221
- 67. Tak PP, Firestein GS (2001) NF-kappaB: a key role in inflammatory diseases. J Clin Invest 107: 7–11. doi: 10.1172/jci11830
- 68. Liu F, Grundke-Iqbal I, Iqbal K, Gong CX (2005) Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur J Neurosci 22: 1942–1950. doi: 10.1111/j.1460-9568.2005.04391.x
- 69. Zhao WQ, Feng C, Alkon DL (2003) Impairment of phosphatase 2A contributes to the prolonged MAP kinase phosphorylation in Alzheimer's disease fibroblasts. Neurobiol Dis 14: 458–469. doi: 10.1016/s0969-9961(03)00124-4
- 70. Vogelsberg-Ragaglia V, Schuck T, Trojanowski JQ, Lee VM (2001) PP2A mRNA expression is quantitatively decreased in Alzheimer's disease hippocampus. Exp Neurol 168: 402–412. doi: 10.1006/exnr.2001.7630
- 71. Hanisch UK, Kettenmann H (2007) Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci 10: 1387–1394. doi: 10.1038/nn1997
- 72. Stossel TP (1993) On the crawling of animal cells. Science 260: 1086–1094. doi: 10.1126/science.8493552
- 73. Mitchison TJ, Cramer LP (1996) Actin-based cell motility and cell locomotion. Cell 84: 371–379. doi: 10.1016/s0092-8674(00)81281-7
- 74. Dehmelt L, Halpain S (2004) Actin and microtubules in neurite initiation: are MAPs the missing link? J Neurobiol 58: 18–33. doi: 10.1002/neu.10284
- 75. Perlmutter LS, Barron E, Chui HC (1990) Morphologic association between microglia and senile plaque amyloid in Alzheimer's disease. Neurosci Lett 119: 32–36. doi: 10.1016/0304-3940(90)90748-x
- 76. Heneka MT, O'Banion MK (2007) Inflammatory processes in Alzheimer's disease. J Neuroimmunol 184: 69–91. doi: 10.1016/j.jneuroim.2006.11.017
- 77. Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, et al. (2007) Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53: 337–351. doi: 10.1016/j.neuron.2007.01.010
- 78. Simard AR, Soulet D, Gowing G, Julien JP, Rivest S (2006) Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron 49: 489–502. doi: 10.1016/j.neuron.2006.01.022
- 79. Shaftel SS, Kyrkanides S, Olschowka JA, Miller JN, Johnson RE, et al. (2007) Sustained hippocampal IL-1 beta overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology. J Clin Invest 117: 1595–1604. doi: 10.1172/jci31450
- 80. Terao A, Apte-Deshpande A, Dousman L, Morairty S, Eynon BP, et al. (2002) Immune response gene expression increases in the aging murine hippocampus. J Neuroimmunol 132: 99–112. doi: 10.1016/s0165-5728(02)00317-x
- 81. Weindruch R, Kayo T, Lee CK, Prolla TA (2002) Gene expression profiling of aging using DNA microarrays. Mech Ageing Dev 123: 177–193. doi: 10.1016/s0047-6374(01)00344-x
- 82. Cakman I, Rohwer J, Schutz RM, Kirchner H, Rink L (1996) Dysregulation between TH1 and TH2 T cell subpopulations in the elderly. Mech Ageing Dev 87: 197–209. doi: 10.1016/0047-6374(96)01708-3
- 83. Pearson VL, Rothwell NJ, Toulmond S (1999) Excitotoxic brain damage in the rat induces interleukin-1beta protein in microglia and astrocytes: correlation with the progression of cell death. Glia 25: 311–323. doi: 10.1002/(sici)1098-1136(19990215)25:4<311::aid-glia1>3.3.co;2-5
- 84. Raivich G, Bohatschek M, Kloss CU, Werner A, Jones LL, et al. (1999) Neuroglial activation repertoire in the injured brain: graded response, molecular mechanisms and cues to physiological function. Brain Res Brain Res Rev 30: 77–105. doi: 10.1016/s0165-0173(99)00007-7
- 85. Cheng B, Christakos S, Mattson MP (1994) Tumor necrosis factors protect neurons against metabolic-excitotoxic insults and promote maintenance of calcium homeostasis. Neuron 12: 139–153. doi: 10.1016/0896-6273(94)90159-7
- 86. Carlson NG, Wieggel WA, Chen J, Bacchi A, Rogers SW, et al. (1999) Inflammatory cytokines IL-1 alpha, IL-1 beta, IL-6, and TNF-alpha impart neuroprotection to an excitotoxin through distinct pathways. J Immunol 163: 3963–3968. doi: 10.1016/s0165-0173(99)00007-7
- 87. Chung HS, Kim SN, Jeong JH, Bae H (2013) A Novel Synthetic Compound 4-Acetyl-3-methyl-6-(2-bromophenyl)pyrano[3,4-c]pyran-1,8-dioneInhibits the Production of Nitric Oxide and Proinflammatory Cytokines Via the NF-kappaB Pathway in Lipopolysaccharide-Activated Microglia Cells. Neurochem Res.
- 88. Bashir A, Haq E (2011) Effect of psychosine on inducible nitric-oxide synthase expression under different culture conditions: implications for Krabbe disease. Eur Rev Med Pharmacol Sci 15: 1282–1287.
- 89. Frost B, Jacks RL, Diamond MI (2009) Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem 284: 12845–12852. doi: 10.1074/jbc.m808759200
- 90. Buerger K, Ewers M, Pirttila T, Zinkowski R, Alafuzoff I, et al. (2006) CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 129: 3035–3041. doi: 10.1093/brain/awl269
- 91. Tapiola T, Overmyer M, Lehtovirta M, Helisalmi S, Ramberg J, et al. (1997) The level of cerebrospinal fluid tau correlates with neurofibrillary tangles in Alzheimer's disease. Neuroreport 8: 3961–3963. doi: 10.1097/00001756-199712220-00022